

**NOTICE OF TERMINATION OF WAFERMINE LICENSING AGREEMENT**

---

The Board of Directors of iX Biopharma Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) refers to the announcement made by the Company on 24 November 2021 in relation to the entry into an exclusive license agreement with Seelos Therapeutics, Inc (the “**Licensee**”) for the licensing of Wafermine, a sublingual racemic ketamine wafer, and other products incorporating R- and S-enantiomers of ketamine utilising the WaferiX technology (the “**License Agreement**”).

The Company wishes to announce that its wholly owned subsidiary, iX Biopharma Europe Limited, has issued a notice of termination (“**Termination Notice**”) of the License Agreement dated 24 November 2021 to the Licensee.

The termination of the License Agreement is not expected to have a material financial impact on the Group. Further announcements will be made by the Company and the Board via SGXNET as and when there are any material developments.

BY ORDER OF THE BOARD

Eddy Lee  
Chairman & CEO

17 November 2023

---

*This announcement has been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President, at 8 Anthony Road, #0101, Singapore 229957, telephone (65) 6590 6881.*